Prenuvo has announced FDA clearance for its AI-powered Prenuvo Body Composition report, marking a significant milestone in the company’s growth. Building on this momentum, Prenuvo introduces three major advances:
- FDA-cleared, AI-powered whole-body composition analysis platform that is non-invasive and delivers precise, actionable, and quantitative data on visceral fat, subcutaneous fat, liver fat, muscle volumes, as well as the volume of vital abdominal organs – providing patients with a personalized report to make informed lifestyle choices and proactive health decisions.
- Groundbreaking new brain health scan that equips patients with critical data on brain function, cognitive health, and early indicators of neurodegenerative conditions.
- Comprehensive functional and conventional blood bio-marker assessment that uses a custom built panel of blood tests to provide insights into metabolic, cardiovascular, hormonal, and immune health. Designed to work symbiotically with imaging to deepen health insights.
These new capabilities will launch immediately in a bundled offering called Prenuvo Enhanced in Silicon Valley, Los Angeles and New York locations, with other locations offering these enhanced screenings in the spring. To sign up for a waitlisted location, visit https://prenuvo.com/enhanced-screening
“Last year demonstrated an unmistakable shift in consumer behavior towards proactive health management,” said Sundeep Peechu, Managing Partner at Felicis. “Prenuvo has a unique integrated model that is difficult to replicate, and their advanced screening positions them to lead this transformation in preventative healthcare.”
The company also disclosed that it has raised $120M as part of Series B fundraising during 2024. The company has identified over 1.4 million personalized health insights across its member base, highlighting the critical role of early detection. This milestone comes as Prenuvo surpassed 110,000 members and secured FDA clearance for its AI-powered Prenuvo Body Composition report.
“Prenuvo is leading a movement to make proactive healthcare accessible and transformative for everyone," said Andrew Lacy, CEO of Prenuvo Inc. "We’re introducing a new approach to early detection that empowers individuals to take control of their health before symptoms emerge. This isn’t just about healthcare; it’s about reimagining how we approach health, using cutting-edge technology and world-class expertise to prevent disease and help people live longer, healthier lives.”
Please visit www.prenuvo.com for additional information.
July 15, 2026 
